Safer Ibogaine Analogs
Opioid Use Disorder
Pre-clinical/ResearchActive (NIDA Grant Funded)
Key Facts
Indication
Opioid Use Disorder
Phase
Pre-clinical/Research
Status
Active (NIDA Grant Funded)
Company
About Gilgamesh Pharmaceuticals
Gilgamesh Pharmaceuticals is a private, clinical-stage biotech leveraging a proprietary AI-powered discovery platform to develop next-generation, non-hallucinogenic neuroplastogens and other novel compounds for major depressive disorder, anxiety, and opioid use disorder. The company has advanced multiple candidates into Phase 2 trials, secured a significant collaboration with AbbVie, and is backed by notable investors like Y Combinator and Prime Movers Lab. With a seasoned leadership team from top biopharma and academia, Gilgamesh is positioned at the forefront of the emerging precision psychiatry sector, aiming to address the global mental health crisis with safer, more effective therapies.
View full company profileOther Opioid Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| TRV734 | Trevena | Phase 1 |
| AM-510 | Aion Medicines | Discovery |
| Naltrexone Implant | Delpor | Phase 1 |
| Platform Expansion | Amygdala Neurosciences | Research |
| Undisclosed OUD Program | Epiodyne | Pre-clinical |
| AQL™-Naltrexone | Plumb Pharmaceuticals | Pre-clinical |
| MEB-1170 | Mebias Discovery | Phase 1 |